Clinical trials: Hydroxychloroquine, completed
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients
Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients
In December 2019, SARS-COV-2 was isolated from patients for the first time . It then rapidly turned into a pandemic affecting the whole world.While most Covid patients survive the disease with mild symptoms, some may develop…
- Trial name
- NCT06223984
- Testing
- pulse steroid and nanogam
- Where
- Turkey (Türkiye)
- Volunteers
- 178 people
- Sponsor
- Konya City Hospital
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Rheumatoid Arthritis
Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
This study will be conducted to find out how well a patient of rheumatoid arthritis (RA) will respond to disease-modifying antirheumatic drugs (DMARDs).
- Trial name
- NCT02644499
- Testing
- Methotrexate, Leflunomide, Hydroxychloroquine
- Where
- India
- Volunteers
- 186 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
COVID-19 Pandemic
Safety and Efficacy of Enoxaparin and Hydroxychloroquine in COVID-19
In this randomized controlled study, two hundred patients with positive PCR and laboratory confirmed COVID-19 will be classified randomly into four groups.
- Trial name
- NCT05311813
- Testing
- Enoxaparin, Hydroxychloroquine
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Beni-Suef University
Immune Thrombocytopenia
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect.
- Trial name
- NCT03229746
- Testing
- Hydroxychloroquine, vincristine, azathioprine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
COVID-19
Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention
This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19.
- Trial name
- HCQ4COV19 (NCT04304053)
- Testing
- Treatment and prophylaxis, Standard Public Health measures
- Where
- Spain
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Cicatricial Alopecia, Lichen Planopilaris
a Retrospective Study on the Systemic Treatment of LPP and FFA
This retrospective study aims to assess the effectiveness of systemic treatments for lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) in patients treated at the Erasmus MC University Medical Center.
- Conditions
- Cicatricial Alopecia, Lichen Planopilaris, Lichen Plano-Pilaris, Frontal Fibrosing Alopecia
- Trial name
- NCT06512766
- Testing
- Hydroxychloroquine, Methotrexate, Cyclosporine A
- Where
- Netherlands
- Volunteers
- 315 people
- Sponsor
- Erasmus Medical Center
Myocardial Infarction, Acute Coronary Syndrome
Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent cardiovascular events among myocardial infarction patients.
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, Inflammation, Hydroxychloroquine
- Trial name
- OXI (NCT02648464)
- Testing
- Hydroxychloroquine
- Where
- 6 sites in Finland
- Volunteers
- 125 people
- Sponsor
- Helsinki University Central Hospital
Corona Virus Infection
Trial of Treatments for COVID-19 in Hospitalized Adults
DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the…
- Trial name
- DisCoVeRy (NCT04315948)
- Testing
- Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A
- Where
- 62 sites in Austria, Belgium and 5 more
- Volunteers
- 1,552 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID, Pneumonia, Viral
Anti Infective Agents Impact in COVID-19 Pneumonia
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al.
- Trial name
- AZITHROVID (NCT04453501)
- Testing
- favorable outcome
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Centre d'Investigation Clinique et Technologique 805
SARS-CoV-2, Systemic Lupus Erythematosus
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients…
- Conditions
- SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- COVCALL (NCT04345159)
- Testing
- Questionnaire by phone call
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
RA
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.
- Trial name
- SARIL-RA-EASY (NCT02057250)
- Testing
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS)
- Where
- 53 sites in United States, Chile and 4 more
- Volunteers
- 217 people
- Sponsor
- Sanofi
Immunosuppression, Rheumatism
To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets
To demonstrate the relative bioavailability of hydroxychloroquine sulfate, 200 mg tablets.
- Trial name
- NCT00946790
- Testing
- Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.), Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sandoz
Rheumatoid Arthritis
Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis
The study has been designed as a 48-week, double-blind, randomized, controlled study comparing the use of leflunomide alone to combinations of leflunomide-sulfasalazine-HCQ, and methotrexate-sulfasalazine-HCQ.
- Trial name
- NCT00579878
- Testing
- Leflunomide, Methotrexate-Sulfasalazine-Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Nebraska
Stage IV Non-small Cell Lung Cancer
Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer
The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).
- Trial name
- NCT02470468
- Testing
- DCVAC add on to SOC, DCVAC and immune enhancers add on to SOC, Standard of Care Chemotherapy
- Where
- 18 sites in Czechia, Slovakia
- Volunteers
- 105 people
- Sponsor
- SOTIO a.s.
Malaria,Falciparum, Anemia in Children
Comparing Chemoprevention Drugs for School-based Malaria Control
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP).
- Trial name
- NCT05980156
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine pyrimethamine
- Where
- Malawi
- Volunteers
- 646 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
This phase I trial studies the best dose of hydroxychloroquine when given together with binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04132505
- Testing
- Binimetinib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19, Favipiravir
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study.
- Conditions
- COVID-19, Favipiravir, Kaletra, Hydroxychloroquine
- Trial name
- NCT04376814
- Testing
- Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Baqiyatallah Medical Sciences University